neoplasm
• beginning at 10 months, mice develop intestinal tumors
• by 13 months, 50% of mice develop intestinal tumors
|
• 63% of tumors
|
• 37% of tumors
|
• mice develop more and smaller tumors than in Msh2tm1Rak/Msh2tm2.1Wed Tg(Vil-cre)20Syr mice
• tumors respond to treatment with cisplatin or FOLFOX unlike tumors from Msh2tm1Rak/Msh2tm2.1Wed Tg(Vil-cre)20Syr mice
|
homeostasis/metabolism
• tumor cells exhibit increased microsatellite instability compared with wild-type cells
|
• tumors respond to treatment with cisplatin or FOLFOX unlike tumors from Msh2tm1Rak/Msh2tm2.1Wed Tg(Vil-cre)20Syr mice
• FOLFOX-treated intestinal mucosa cells exhibit decreased apoptosis compared with similarly treated cells from Msh2tm2.1Wed homozygotes but increased compared with similarly treated cell from Msh2tm1Rak/Msh2tm2.1Wed Tg(Vil-cre)20Syr mice
|
cellular
• tumor cells exhibit increased microsatellite instability compared with wild-type cells
|
digestive/alimentary system
• beginning at 10 months, mice develop intestinal tumors
• by 13 months, 50% of mice develop intestinal tumors
|
• 63% of tumors
|
• 37% of tumors
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
Lynch syndrome | DOID:3883 |
OMIM:PS120435 |
J:161577 |